GILD

ABBV AMGN AMGN:CA BAYRY BAYZF Biotechnology BMY GILD IPSEF IPSEY JNJ JNJ:CA LLY LLY:CA NONOF NOVO:CA NVO NVON:CA NVS NVS:CA NVSEF PFE PFE:CA REGN RHHBF RHHBY RHHVF Robert J. Lake ROCH:CA ROG:CA SAN:CA SNY SNY:CA SNYNF Uncategorized VRTX ZLLY:CA ZPFE:CA

Regeneron: Fairly Valued Now After A Stellar Upswing

Mar 11, 2026

Biotechnology GILD Uncategorized

Gilead in talks with South Africa to start local production of new HIV therapy

Mar 6, 2026

AZN Biotechnology CGEN GILD GILD:CA Terry Chrisomalis Uncategorized

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Mar 2, 2026

Biotechnology GILD Uncategorized

Gilead phase 3 data shows continued viral suppression with HIV combo pill

Feb 25, 2026

Biotechnology Edmund Ingham GILD GILD:CA Uncategorized VIR

Vir Biotechnology: Up On Prostate Data And Astellas Deal – I’m (Long-Term) Bullish

Feb 24, 2026

ACLX Biotechnology GILD JNJ LEGN ONeil Trader Uncategorized

What Gilead Is Getting Through The Acquisition Of Arcellx

Feb 23, 2026

ALLKA Research Biotechnology GILD GILD:CA GLAXF GNFTF GNFTY GSK IPSEF IPSEY JNJ JNJ:CA MRK MRK:CA Uncategorized

Time To Take Profits On Gilead Sciences (Rating Downgrade)

Feb 20, 2026

Biotechnology CVS GILD MDT MRNA Uncategorized XLV

Earnings Scorecard: Healthcare sector shows strong top-line pulse

Feb 14, 2026

Biotechnology GILD Uncategorized

Gilead falls despite quarterly beats on disappointing 2026 EPS guidance

Feb 10, 2026

Biotechnology GILD Uncategorized

Gilead Sciences Non-GAAP EPS of $1.86 beats by $0.03, revenue of $7.93B beats by $250M

Feb 10, 2026

Next Page »